News | October 08, 2013

World Molecular Imaging Congress Features Scientific Breakthroughs in Molecular Multimodal Imaging

October 8, 2013 — The World Molecular Imaging Society (WMIS) held its sixth annual congress in Savannah, Ga. Sept. 18-21.  The World Molecular Imaging Congress (WMIC) 2013 featured advancements in molecular multimodal imaging with a focus on discovery, pre-clinical and translational research, highlighting first-in-human studies that drive innovative diagnostics and targeted therapy critical to the implementation of precision medicine.  

“Molecular imaging and targeted therapy are essential to the successful implementation of precision medicine,” said Hedvig Hricak M.D., Ph.D., chairman, radiology; Memorial Sloan-Kettering Cancer Center and one of eight plenary speakers at the WMIC 2013. “The WMIC is a unique international forum for discussing all aspects of molecular imaging research, from an idea to preclinical studies to first-in-human imaging trials. The WMIS is taking the lead in the global discussions of MI and its clinical applications and it is a pleasure and honor to take part in the 2013 WMIS annual meeting."

The program consisted of 168 oral presentations and 35 spotlight presentations emphasizing five categories: Chemistry and Imaging Probes, First-in-Human and Clinical Studies, Preclinical Cell and Tissue Level Studies, Preclinical In Vivo Studies and Technology and Software development.

For more information: www.wmicmeeting.org

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...